Literature DB >> 1156027

Etomidate, a potent non-barbiturate hypnotic. Intravenous etomidate in mice, rats, guinea-pigs, rabbits and dogs.

P A Janssen, C J Niemegeers, R P Marsboom.   

Abstract

Etomidate, R-(+)-ethyl-1-(1-phenylethyl)-1H-imidazole-5-carboxylate was found to be a potent, short-acting and safe hypnotic; when given intravenously in single doses to mice, rats, guinea-pigs, rabbits and dogs. In rats of different body weight (50, 100, 200 and 300 g) two injection rates were used (2 sec and 2 min). By rapid iv injection in rats of 200 g etomidate (ED50 equal to 0.57 mg/kg) is about 6 times more potent than methohexital (ED50 equal to 3.51 mg/kg) and 25 times more potent than propanidid and thiopental (ED50's equal to 13.4 mg/kg). The safety margin (LD50/ED50) in these rats is 26.0 for etomidate, 9.5 for methohexital, 6.7 for propanidid and 4.6 for thiopental. Potency and toxicity of etomidate slightly increase with increasing injection rates without affecting the safety margin. The duration of hypnosis with etomidate is dose-dependent and the safety margin will therefore be widened when sleep of short duration is aimed at. Recovery after etomidate is very rapid. With lower body weights, higher doses in mg/kg are required for inducing hypnosis of comparable duration. No systematic differences were found after etomidate injection in incidence and duration of hypnosis nor in mortality between animals of different sex. ECG, blood pressure, haematological and biochemical analysis, urinalysis and histopathology did not reveal any drug-related adverse effect after daily injection of etomidate for 3 weeks in rats (highest dose 5.0 mg/kg) and 2 weeks in dogs (highest dose 1.50 mg/kg). No tolerance was observed after repeated administration. Etomidate is devoid of any teratogenic effect in rats (highest dose: 5.0 mg/kg daily from day 6 through day 15 of pregnancy), and in New Zealand white rabbits (highest dose: 4.5 mg/kg daily from day 6 through day 18 of pregnancy). The hypnotic effects of etomidate at very low dose levels in different laboratory animals are compared with the effects obtained in human subjects, in which successful induction of anaesthesia was obtained without producing any release of histamine and with only minimal effects on cardiovascular and respiratory functions.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1156027

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  10 in total

1.  What is the optimal anesthetic protocol for measurements of cerebral autoregulation in spontaneously breathing mice?

Authors:  Zhenghui Wang; Beat Schuler; Olga Vogel; Margarete Arras; Johannes Vogel
Journal:  Exp Brain Res       Date:  2010-10-24       Impact factor: 1.972

Review 2.  Clinical and molecular pharmacology of etomidate.

Authors:  Stuart A Forman
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

3.  Proceedings of the British Pharmacological Society. 9th-11th September 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-12       Impact factor: 8.739

4.  Analogues of etomidate: modifications around etomidate's chiral carbon and the impact on in vitro and in vivo pharmacology.

Authors:  Ervin Pejo; Peter Santer; Spencer Jeffrey; Hilary Gallin; S Shaukat Husain; Douglas E Raines
Journal:  Anesthesiology       Date:  2014-08       Impact factor: 7.892

5.  Etomidate-anaesthesia, with and without fentanyl, compared with urethane-anaesthesia in the rat.

Authors:  D J De Wildt; F C Hillen; A G Rauws; B Sangster
Journal:  Br J Pharmacol       Date:  1983-06       Impact factor: 8.739

6.  The indices of potency for intravenous anaesthetics.

Authors:  I Kissin; T McGee; L R Smith
Journal:  Can Anaesth Soc J       Date:  1981-11

7.  Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion.

Authors:  Dandan Geng; Yan Li; Chunyan Wang; Bo Ren; Heping Wang; Chensi Wu; Yirong Zhang; Linlin Zhao; Ligang Zhao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 8.  Pro/con debate: Is etomidate safe in hemodynamically unstable critically ill patients?

Authors:  Gordon Flynn; Yahya Shehabi
Journal:  Crit Care       Date:  2012-07-19       Impact factor: 9.097

Review 9.  Pharmacological management of severe Cushing's syndrome: the role of etomidate.

Authors:  Andrea Pence; Megan McGrath; Stephanie L Lee; Douglas E Raines
Journal:  Ther Adv Endocrinol Metab       Date:  2022-02-14       Impact factor: 3.565

Review 10.  Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics.

Authors:  Beatrijs I Valk; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2021-06-01       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.